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Abstract
Background: The b-amino acid, taurine, is a nutritional requirement in some species. In these species, the
depletion of intracellular stores of taurine leads to the development of severe organ dysfunction. The basis
underlying these defects is poorly understood, although there is some suggestion that oxidative stress may
contribute to the abnormalities. Recent studies indicate that taurine is required for normal mitochondrial protein
synthesis and normal electron transport chain activity; it is known that defects in these events can lead to severe
mitochondrial oxidative stress. The present study examines the effect of taurine deficiency on the first step of
mitochondrial protein synthesis regulation by taurine, namely, the formation of taurinomethyluridine containing
tRNA.
Methods: Isolated rat cardiomyocytes were rendered taurine deficient by incubation with medium containing the
taurine transport inhibitor, b-alanine. The time course of cellular and mitochondrial taurine depletion was
measured. The primer extension method was employed to evaluate the effect of b-alanine treatment on
taurinomethyluridine content of tRNA
Leu. The protein levels of ND6 were also determined by Western blot analysis.
Results: b-alanine caused a time-dependent decrease in cellular taurine content, which were reduced in half after
48 hrs of incubation. The amount of taurine in the mitochondria was considerably less than that in the cytosol and
was unaffected by b-alanine treatment. Approximately 70% of the tRNA
Leu in the untreated cell lacked
taurinomethyluridine and these levels were unchanged following b-alanine treatment. Protein content of ND6,
however, was significantly reduced after 48 hours incubation with b-alanine.
Conclusions: The taurine levels of the cytosol and the mitochondria are not directly coupled. The b-alanine-
mediated reduction in taurine levels is too small to affect taurinomethyluridine levels. Nonetheless, it interferes with
mitochondrial protein synthesis, as exemplified by a decrease in ND6 protein content. Thus, b-alanine does not
cause alterations in mitochondrial protein synthesis through the lowering of taurine levels.
Background
Taurine is a b-amino acid found in high concentrations
in most tissues, with levels being particularly high in
excitable tissue [1-3]. Although taurine was identified as
a component of biological material as early as 1827, its
physiological functions have not been adequately identi-
fied. Among the recognized actions of taurine are
osmoregulation, membrane modulation, antioxidation,
cytoprotection, anti-inflammation and regulation of ion
transport [4-8]. Many of these actions are attributed to
one or more of its biochemical reactions, which include
conjugation [4], modulation of protein phosphorylation
status [5], alteration in phospholipid N-methylation [6],
neutralization of hypochlorous acid [9] and regulation of
ion transport [10].
The link between the biochemical reactions of taurine
and the overt consequences of taurine deficiency, such as
immune deficiency, stunted growth, birth defects and the
development of a retinopathy and cardiomyopathy
[7,11-14], remain unclear. Because many cardiomyopathies
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excessive reactive oxygen species (ROS) production may
contribute to the development of the taurine deficient car-
diomyopathy seems reasonable [8]. However, the mechan-
ism by which taurine modulates oxidative stress has been
enigmatic. Not only is taurine incapable of functioning as
a classical free radical scavenger [15], but there is no con-
crete evidence that it upregulates the antioxidant defenses
of the cell. Recently, it has been proposed that taurine
might indirectly modulate the production of ROS by the
mitochondria [16]. According to the proposal of Schaffer
et al.[16], the initial step in taurine deficiency-mediated
ROS generation is a decline in the 5-taurinomethyluridine
content of mitochondrial tRNA
Leu.B e c a u s et h ec o n j u g a -
tion of taurine with a key uridine moiety of mitochondrial
tRNA
Leu enhances the binding of tRNA to the codon of
mRNA [17], decreases in 5-taurinomethyluridine content
lead to diminished rates of mitochondrial encoded protein
synthesis. According to Kirino et al.[17], translational defi-
ciencies develop in tRNA
Leu containing the anticodon,
UAA, and lacking 5-taurinomethyluridine. Because the
UAA anticodon interacts weakly with the codon UUG but
not to the codon UUA, the translational defect only occurs
with mRNAs containing the UUG codon. In turn, lower
rates of protein synthesis interfere with the normal assem-
bly of the respiratory chain complexes, which consist of
both nuclear and mitochondria encoded proteins. It is well
recognized that reduced levels of the respiratory chain
complexes result in impaired flux of electrons through the
electron transport chain. Consequently, the efficiency of
the electron transport chain declines, as electrons are
diverted from the electron transport chain to oxygen,
forming in the process superoxide. There is some prece-
dence for this hypothesis. Kirino et al.[18] observed that a
group of patients with symptoms of mitochondrial myopa-
thy, encephalopathy, lactic acidosis and stroke-like epi-
sodes (MELAS) contain several mitochondrial tRNA
mutations, which lead to a lack of the 5-taurinomethyluri-
dine moiety.
A major assumption of the Schaffer hypothesis [16] is
that a decline in intracellular taurine levels inevitably
leads to a decrease in the formation of 5-taurinomethy-
luridine. However, very little information is available on
the relationship between cellular taurine levels and
mitochondrial taurine content. Moreover, the depen-
dence of 5-taurinomethyluridine formation on mito-
chondrial taurine levels remains to be established.
Further, the assumption that reduced 5-taurinomethy-
luridine levels decrease the expression of a protein,
whose mRNA contains high levels of the UUG codon,
needs further study. To evaluate the validity of these
assumptions, the present study examines the effect of
drug-mediated taurine depletion on mitochondrial taur-
ine content and the conjugation of mitochondrial
tRNAs in isolated neonatal cardiomyocytes. Also exam-
ined is the expression of ND6, whose mRNA contains
8 UUG codons [17]. To decrease cellular taurine con-
tent, isolated cardiac cells were exposed to the taurine
transport inhibitor, b-alanine [19-21]. Previous studies
have shown that b-alanine-mediated taurine deficiency
is associated with impaired rates of cardiomyocyte
relaxation, changes in cell size and alterations in calcium
movement [21,22].
Methods
Cardiomyocytes preparation and incubation conditions
Neonatal cardiomyocytes were prepared from 2-3-day
old Wistar rats as described previously by Grishko et al.
[23]. The use of animals for this study was approved by
the Institutional Animal Care and Use Committee.
Hearts were removed and the ventricular tissue was
minced. Cells were isolated by four 30-minute cycles of
enzymatic digestion with a mixture of trypsin, chymo-
trypsin and elastase (Calbiochem) in HEPES-buffered sal-
ine solution at 37
oC. After dissociation, cells were pre-
plated on plastic culture dishes for 90 minutes at 37
oCt o
allow for nonmyocyte attachment. After the incubation
period, the number of cells in the myocyte suspension
was counted with a hemacytometer. The unattached cells
were then suspended in minimum essential medium
(MEM), containing 10% newborn calf serum and 0.1 mM
5-bromo-2-deoxyuridine. The cells were plated and incu-
bated overnight to allow for attachment of viable cardio-
myocytes. The serum-containing medium was replaced
the next day with serum-substitute. The neonatal cardio-
myocyte culture was maintained for 2 days at 37
oCp r i o r
to being subjected to medium containing 0 mM (Con-
trol) for 48 hours or 5 mM b-alanine for 4 hours,
16 hours, 24 hours or 48 hours.
Measurement of intracellular taurine levels
In order to measure intracellular taurine content, cells
were first scraped from the dish and homogenized in ice
cold 1 M perchloric acid and 2 mM EDTA. Homoge-
nates were centrifuged at 10,000 g for 10 minutes at
4 °C. The supernatant was neutralized to pH 5-6 using
2M KOH and centrifuged again at 10,000 g for 10 min-
utes at 4 °C. The resulting supernatant (2-5 ml) was
passed through Dowex-50 X 8 (200-400 mesh, 9 X 40-
55 mm) columns and eluted with 2 ml of deionized
water. An aliquot of the eluant was used to measure
taurine levels using the procedures described by Shaffer
and Kocsis [24]. A taurine standard curve was developed
using 2-40 µg taurine for each assay.
Primer extension method
The primer extension method described by Kirino et al.
(18) was used to detect changes in the levels of
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Leu in b-
alanine-treated cells. Total RNA was first isolated from
cells using Trizol LS Reagent (Invitrogen; Carlsbad, CA)
according to the protocol. The RNA samples were incu-
bated at 80 °C for 2 minutes in 10 mM Tris-HCl pH 8.0
buffer containing 1 mM EDTA and a
32P-labeled primer
of mitochondrial tRNA
Leu (0.1 pmol of 5′-ACCTCT
GGGAAGG-3′). The samples were then allowed to cool
at room temperature for 1 hour. To initiate the primer
extension reaction, RNase-free H2O, 5X reaction buffer
required for reverse transcription reactions, a d/ddNTP
mixture containing dATP, dTTP and ddGTP, 25 mM
MgCl2 and Moloney murine leukemia virus reverse
transcriptase were added. The mixture was incubated
at 42 °C for 1 hour. The reaction mixture was subjected
to polyacrylamide gel electrophoresis containing 7 M
urea. The radiolabeled bands were visualized by
autoradiograph.
Western blot analysis
To detect a specific protein, western blot analysis was
performed according to the protocol described by
Grishko et al. [23]. Cells were washed twice in buffer
containing 250 mmol/L sucrose, 10 mmol/L triethanola-
mine, pH 7.6, at room temperature. Next, cells were
lysed in ice cold isolation buffer. The homogenate was
centrifuged at 800 g for 6 minutes at 4
0C and the super-
natant was retrieved and centrifuged again at 16,000 g
for 20 minutes at 4
0C. The pellet was defined as the
mitochondrial fraction and used to determine ND6 and
succinate dehydrogenase content. The pellet was sus-
pended in RadioImmuno Precipitation Assay (RIPA)
lysis buffer. Protein concentration was determined by
the bicinchoninic acid (BCA) method. The mitochon-
drial sample was mixed with an equal volume of 5X
electrophoresis sample buffer and the samples were then
boiled for 3 minutes before being analyzed. During
Western blot analysis, mitochondrial samples were sub-
jected to one-dimensional electrophoresis using 12%
SDS PAGE. The proteins were then transferred to nitro-
cellulose membranes and the membranes were blocked.
After incubation with the appropriate antibody, the
membranes were washed and then incubated with a sec-
ondary antibody. The Western blots were analyzed by
the enhanced chemiluminescence reaction.
Results
Effect of b-alanine on intracellular taurine levels
Exposure of isolated neonatal cardiomyocytes to taurine
transport inhibitor, b-alanine (5mM) resulted in a time-
dependent decline in intracellular taurine levels (Figure
1A). Following 4 hours of b-alanine treatment, cellular
taurine content declined only 10%. The rate of taurine
depletion subsequently accelerated, with levels reaching
50% of normal by 48 hours of treatment. When normal-
ized relative to protein content, the mitochondrial con-
tent of taurine was ~30% of total cellular levels.
Surprisingly, mitochondrial taurine level was unaffected
by the exposure of the cells to b-alanine (Figure 1B).
Effect of taurine depletion on taurine conjugation of
mitochondrial tRNA
Leu
Using the primer extension method, we found that b-ala-
nine-mediated taurine depletion did not affect the taurino-
methyluridine content of mitochondrial tRNA
Leu(UUR)
(Figure 2). Because modified uridine (τm
5U) hinders the
reverse transcription reaction, the primer extension
method readily detects changes in 5-taurinomethyluridine
content. While extension of the primer terminates one
base after the modified uridine in the case of tRNA
containing modified uridine, if the tRNA lacks the
Figure 1 Effect of b-alanine treatment on taurine content
Isolated neonatal cardiomyocytes were incubated with 5 mM b-
alanine for various period of time. Intracellular taurine levels were
determined as described in the methods. (A) b-alanine treatment
reduces intracellular taurine content. Values shown represent means
± S.E.M. of 4-5 preparations. *Significant difference between b-
alanine-treated groups and Control (p<0.05). (B) Mitochondrial
taurine levels were unaffected by b-alanine treatment. Values shown
represent means ± S.E.M. of 5-6 preparations.
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ceeds beyond the unmodified uridine (U). Figure 2A
shows each species formed when the reverse transcriptase
is added to medium containing a mixture of primer,
tRNA
Leu(UUR), dTTP, dATP and ddGTP, the latter which
terminates the reverse transcriptase reaction. Because the
primer is complimentary to the TGGAGACCCTTCC
sequence of the tRNA, the extension reaction adds
TTTTAA to the primer of the τm
5Uf o r mo ft R N Ab u t
TTTTAAG to the U form of tRNA. As seen in Figure 2B,
two primer extension species are produced, which show
up on the gel as two specific bands. The U band repre-
sents primer from tRNA containing unmodified uridine
and the τm
5U band represents primer from tRNA contain-
ing modified uridine. In the untreated cells, approximately
1/3 of tRNA
Leu(UUR) contains modified uridine and the
remainder unmodified uridine. Figure 2B also shows that
b-alanine treatment had no effect on the relative levels of
the U and τm
5U forms of tRNA
Leu(UUR).
Effect of taurine deficiency on ND6 protein level
Our western blot analysis showed a reduction in the
expression of ND6, a subunit of complex I of the
respiratory chain, in b-alanine-treated cells. As shown in
Figure 3, a significant reduction of 60% was observed at
48 hours, indicating that b-alanine decreases the expres-
sion of a mitochondrial-encoded protein, whose mRNA
contains a high content of the UUG codon. A represen-
tative gel of ND6 is also shown in Figure 3.
Discussion
The most important finding of this study is that drug-
mediated taurine depletion initiates a time-dependent
decline in cellular taurine content that is not associated
with a decline in either mitochondrial taurine content
or the 5-taurinomethyluridine content of mitochondrial
tRNA
Leu.Y e t ,w ef o u n dt h a tb-alanine treatment
induces a significant reduction in mitochondrial protein
expression of ND6. Based on the results of the primer
extension procedure, we also conclude that ~67% of the
tRNA
Leu in the untreated cells lacks the 5-taurinomethy-
luridine moiety. Based on the relative amount of primer
that is not terminated at the taurinomethyluridine step,
less than 33% of tRNA
Leu in the control cells contains
5-taurinomethyluridine (Figure 2). Moreover, exposure
of the cells to medium containing the taurine transport
Figure 2 Effect of b-alanine-mediated taurine depletion on
wobble uridine modification (A) The primer extension method
was used to detect levels of 5-taurinomethyluridine in
mitochondrial tRNA
Leu(UUR) before and following b-alanine-
treatment. Shown is a representative gel of reverse transcription
from the primer. A defect in uridine modification resulted in the
extension of reverse transcription through the unmodified uridine
(U*), which terminated at cytosine (C) due to the inclusion of
dideoxyguanosine (ddGTP) in the reaction mixture. (B) Exposure of
cardiomyocytes to b-alanine at various time intervals did not cause
a significant change in either modified (τm
5U) or unmodified
uridine (U).
Figure 3 Effect of taurine deficiency on protein levels of ND6
Cardiomyocytes were exposed to medium containing 5 mM b-
alanine for 48 hours. Mitochondria were subjected to Western blot
analysis of ND6. (A) Shown is a representative gel of ND6 and
succinate dehydrogenase (SDH). (B) Values shown represent means
± S.E.M. of the ND6/SDH ratio of 6-7 preparations. *Significant
difference between b-alanine-treated group and Control (p<0.05).
Jong et al. Journal of Biomedical Science 2010, 17(Suppl 1):S25
http://www.jbiomedsci.com/content/17/S1/S25
Page 4 of 7inhibitor, b-alanine (5 mM), has no apparent effect on
the taurinomethyluridine content of tRNA
Leu.
The present study also shows that mitochondrial taur-
ine content pales in comparison with taurine content of
the whole cell. This is not surprising because taurine
serves as an important osmolyte in the heart, which
necessitates a high concentration of the b-amino acid in
the cytosol [25]. However, Suzuki et al.[26] found that
mitochondrial tRNA
Leu isolated from HeLa cells grown
in medium containing
18O-taurine is labeled with
18O-
taurinomethyluridine, indicating that 5-taurinomethylur-
idine levels are maintained in part by extracellular taur-
ine. Moreover, taurine is readily taken up by isolated
bovine mitochondria [26]. Nonetheless, the present
study uncovered an uncoupling between changes in
taurine content of the cytosol and the mitochondria.
While whole cellular taurine levels declined in a time
d e p e n d e n tm a n n e rb ya sm u c ha s5 0 %u p o ne x p o s u r e
to b-alanine, mitochondrial taurine content remained
unaffected (Figure 1). This finding suggests that either
the decline in cytosolic taurine has no influence on
mitochondrial taurine uptake or the turnover of taurine
by the mitochondria is very low. The former seems
more reasonable, based on the work of Huxtable and
Bressler [27], who found that very little
14C-taurine
injected into rats are distributed to the mitochondria
while large amounts end up in the cytosol.
The mechanism by which taurine enters the mito-
chondria from the cytoplasm is completely unknown.
Although Suzuki et al.[26] first identified the existence
of a mitochondrial transport event, they failed to charac-
terize it. Nonetheless, it is logical to assume that the
mitochondrial transporter is mechanistically and struc-
turally different from the most widely studied taurine
transporter, the Na
+/Cl
- dependent transporter located
on the cell membrane of a wide range of cell types
[28-30]. A key difference between the two transporters
lies in the need to transport taurine against a huge con-
centration gradient in the case of the cell membrane
transporter vs. little if any gradient in the case of the
mitochondrial transporter. Although taurine transport
was not examined in the present study, we showed that
the decrease in cytosolic taurine levels mediated by b-
alanine treatment only reduce the concentration of cel-
lular taurine from ~30 mM to ~15 mM. Because most
transporters are characterized by Km values in the μM
to low mM range, the mitochondrial transporter is likely
to have a Km for taurine in the 1-10 mM range. The
high cytosolic taurine levels may explain the failure of
b-alanine treatment to affect mitochondrial taurine con-
tent, as 15 mM taurine would likely saturate the taurine
binding sites of the mitochondrial transporter. However,
it remains to be determined if more severe cytosolic
taurine deficiency is capable of affecting mitochondrial
taurine levels.
Kirino and colleagues [17] have suggested that the
conjugation of mitochondrial tRNA by taurine ensures
the proper expression of mitochondrial proteins.
According to their theory, proteins whose mRNA con-
tains large amounts of the UUG codon would be parti-
cularly sensitive to reduced taurine conjugation of
tRNA
Leu. The mRNA of ND6 contains 8 UUG codons.
In fact, 42% of the leucine codons of ND6 are UUG
codons. Therefore, the present study showing that b-ala-
nine-treated cells exhibit a significant decline in ND6
protein levels (Figure 3) is in apparent agreement with
the idea that taurine is essential for normal protein
synthesis. However, b-alanine was not associated with a
significant decrease in mitochondrial taurine and pre-
s u m a b l yn oc h a n g ei n5 - t a u r i nomethyluridine levels,
which is in disagreement with the hypothesis of Kirino
et al.[17]. These data imply that b-alanine acts at some
other site in the synthesis of ND6. A logical possibility
is that b-alanine conjugates with uridine, a reaction that
could weaken the anticodon-codon interaction involving
tRNA
Leu. Therefore, b-alanine might interfere with the
actions of taurine by weakening the U:G wobble base
pairing, thereby reducing the synthesis of ND6.
A key question is whether the present findings provide
insight into the development of pathological lesions in
the taurine deficient cell. It has been shown that treat-
ment of animals or cells with one of the taurine trans-
port inhibitors, b-alanine or guanidinoethanesulfonate,
decrease taurine levels by nearly 50% and lead to the
development of specific pathological lesions. However,
nutritional depletion of taurine in some species, such as
fox, cats, and monkeys, result in the loss of up to 90-
95% of myocardial taurine and lead to the development
of overt cardiomyopathy [14,31] and retinopathy [12],
severe developmental defects [13] and immunological
deficiencies [7]. Fox, cats, some breeds of dogs and
monkeys share two characteristics that drive severe taur-
ine depletion and the appearance of cardiac and retinal
lesions. First, they lack a robust pathway for taurine bio-
synthesis [32,33]. Second, they preferentially utilize taur-
ine to conjugate bile acids [32,33]. Because bile acids
serve as the most abundant sink for taurine and are lost
on a daily basis in the feces, an imbalance readily devel-
ops between the supply and loss of taurine in the nutri-
tionally deficient cat. Interestingly, humans lack a robust
taurine biosynthetic pathway, but they can substitute
glycine for taurine in the conjugation of bile acids; the
bile acid requirement spares humans severe taurine defi-
ciency and its pathological consequences [34].
The rat readily synthesizes taurine in the liver [35].
Because the heart lacks a robust taurine synthetic
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maintain high intracellular levels. Huxtable [35] has
shown that the taurine transport inhibitors diminish car-
diac taurine levels by blocking both taurine transport
and biosynthesis. One of these inhibitors, guanidinoetha-
nesulfonate, has been shown to cause contractile dys-
function and the loss of myofibrils in the heart of
treated rats [36,37]. However, guanidinoethanesulfonate
diminishes the levels of creatine phosphate, an impor-
tant energy metabolite in the heart, raising questions
about the appropriateness of using guanidinoethanesul-
fonate to study the effects of taurine deficiency on heart
function [38]. The other major taurine transport inhibi-
tor, b-alanine, causes modest defects in myocardial
relaxation, which have been attributed to impaired Ca
2+
handling by the sarcoplasmic reticulum [22].
The damage caused by taurine deficiency in the nutri-
tionally deficient cat is much more severe. Pion et al.
[14] and Novotny et al.[32] have shown that cats fed a
taurine deficient diet develop a severe cardiomyopathy,
characterized by dilation of the left ventricle chamber
and both systolic and diastolic dysfunction. Because
myocardial taurine levels are decreased by >99% in these
animals [32], it would be interesting to assess the effects
of this severely depleted taurine model on mitochondrial
taurine and taurinomethyluridine content. It would also
be of interest to evaluate the effect of severe taurine
depletion on oxidative stress, which can arise from
impaired mitochondrial protein synthesis secondary to
taurine-deficient-mediated changes in tRNA
Leu.
Conclusions
In conclusion, our data show that b-alanine initiates a
time-dependent decline in cellular taurine content, but
does not cause a reduction in mitochondrial taurine
levels or the 5-taurinomethyluridine content of mito-
chondrial tRNA
Leu.
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